| Utestående aksjer | 112,873,552 shares |
| Innsideraksjer | 161 383 910 shares |
| Totale insidere | 17 |
Insider Sentiment Score
Insider Sentiment Score finner selskapene som blir kjøpt av bedriftsinsidere.
Det er resultatet av en sofistikert, flerfaktor kvantitativ modell som identifiserer selskaper som har de høyeste nivåene av insiderakkumulasjon. Scoringsmodellen bruker en kombinasjon av netto antall insidere som kjøper de siste 90 dagene, det totale antallet kjøpte aksjer som en prosentandel av flyten, og det totale antallet aksjer eid av insidere. Tallet varierer fra 0 til 100, hvor høyere tall indikerer en høyere grad av akkumulasjon sammenlignet med jevnaldrende, og 50 er gjennomsnittet.
Oppdateringsfrekvens: Daglig
Se Insidernes Topp Picks, som gir en liste over selskaper med høyest akkumulasjon blant insidere.
Officer Sentiment Score
Officer Sentiment Score finner selskaper som kjøpes av bedriftsoffiserer.
Per definisjon er Corporate Officers Corporate Insiders, men i motsetning til noen av de andre innsiderne (10 % aksjonærer og styremedlemmer), jobber offiserer for selskapet på daglig basis, og de bruker sine egne penger når de handler . (10 % aksjonærer og styremedlemmer er ofte fondsforvaltere som forvalter andres penger.) Som sådan er innsidehandler utført av offiserer mye mer betydningsfulle og bør behandles på riktig måte.
Som Insider Sentiment Score er Officer Sentiment Score resultatet av en sofistikert, flerfaktor kvantitativ modell som identifiserer selskaper med de høyeste nivåene av akkumulasjon blant ledelsen.
Oppdateringsfrekvens: Daglig
Se Insidernes Topp Picks, som gir en liste over selskaper med høyest insider-sentiment.
Nøkkelindikatorer for insidere
Dette kortet viser hvordan selskapet rangerer langs ulike indikatorer for insidere. Percentile-rangeringen viser hvordan dette selskapet sammenligner seg med andre selskaper på USAs markeder. Høyere rangeringer indikerer bedre situasjoner.
For eksempel, er det generelt akseptert at insiderkjøp er en positiv indikator, så derfor ville selskaper som insiderkjøper mer, rangere høyere enn selskaper med mindre insiderkjøp (eller til og med insidersalg).
Prosent av aksjeflyt kjøpt av insidere (rang)
0.000 %( )
8828 out of 11227Prosenten av aksjeflyt kjøpt av innsidere er det totale antallet aksjer som er blitt kjøpt av innsidere minus det totale antallet aksjer solgt av innsidere de siste 90 dagene, delt på totalt antall utestående aksjer og multiplisert med 100.
Diagram over innsidehandel
Vaxxinity, Inc. insiderhandel vises i følgende diagram. Innsidere er ledere, direktører eller viktige investorer i et selskap. Generelt sett er det ulovlig for insidere å handle med aksjer i sine selskaper basert på materiell, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre any handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via en Form 4.
Insiderliste og lønnsomhetsmålinger
Denne tabellen viser listen over kjente insidere, og er automatisk generert fra arkiveringer offentliggjort av SEC. I tillegg til navn, siste tittel og direktør-, offiser- eller 10 % eier-betegnelse, gir vi de nyeste offentliggjorte beholdningene. I tillegg gir vi, når det er mulig, den historiske handelsytelsen for insidere. Den historiske handelsytelsen er et vektet gjennomsnitt av ytelsen til faktiske kjøpstransaksjoner som er gjort av insidere på det åpne markedet. For mer informasjon om hvordan dette blir beregnet, kan du se dette YouTube-webinaret.
See our leaderboard of most profitable insider traders.
| Innsider | Gjennomsnittlig fortjeneste (%) | Aksjer eid |
Splitt justert |
|---|---|---|---|
| Gregory R Blatt Director - [D] | 76 923 | 76 923 | |
| James Chui Director - [D] | 14 000 | 14 000 | |
| Peter Diamandis Director - [D] | 2 019 880 | 2 019 880 | |
| Martin Doran See Remarks - [O] | 22 688 | 22 688 | |
| Farshad Guirakhoo (Former) Chief Scientific Off. - [O] | 68 645 | 68 645 |
| Innsider | Gjennomsnittlig fortjeneste (%) | Aksjer eid |
Splitt justert |
|---|---|---|---|
| George R Hornig | 67 953 | ||
|
Mei Mei Hu
See Remarks, Director, 10% Owner -
[D]
[O]
|
51 737 344 | 51 737 344 | |
| Landon E Ogilvie Director - [D] | 32 850 | 32 850 | |
| Ulo Palm Chief Medical Officer - [O] | 450 | 450 | |
| Molina Rene Paula | 96 153 | ||
| Jason Pesile | 51 225 |
| Innsider | Gjennomsnittlig fortjeneste (%) | Aksjer eid |
Splitt justert |
|---|---|---|---|
| Peter Powchik Director - [D] | 225 858 | 225 858 | |
|
Prime Movers Lab Fund I LP
10% Owner -
|
3 594 122 | 3 594 122 | |
|
Lou Reese
Executive Chairman, Director, 10% Owner -
[D]
[O]
|
51 737 344 | 51 737 344 | |
|
Dakin Sloss
10% Owner -
|
9 738 192 | 3 594 122 | |
| James Alan Smith Director - [D] | 116 462 | 116 462 | |
|
United Biomedical Inc
10% Owner -
|
51 737 344 | 51 737 344 |
Report errors via our new Insider Auditing Tool
Analyse av sporrekord for insiderkjøp - Kortsiktig lønnsomhetsanalyse
I denne seksjonen analyserer vi lønnsomheten til hver ikke-planlagte, åpne markeds innsidekjøp gjort i VAXX / Vaxxinity, Inc.. Denne analysen hjelper til med å forstå om insidere konsekvent genererer unormale avkastninger og er verdt å følge. Denne analysen gjelder for ett år etter hver handel, og resultatene er teoretiske .
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en automatisk handelsplan.
Justert pris er prisen justert for splitt. Justerte aksjer er aksjer justert for splitt.
Analyse av sporrekord for insidesalg - Kortsiktig tapanalyse
I denne seksjonen analyserer vi kortsiktig tap til hver ikke-planlagte, åpne markeds innsidekjøp gjort i VAXX / Vaxxinity, Inc.. Et konsekvent mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder for ett år etter hver handel, og resultatene er teoretiske .
Følgende tabell viser de mest nylige åpne markedssalgene som ikke var en del av en automatisk trading plan.
Justert pris er prisen justert for splitt. Justerte aksjer er aksjer justert for splitt.
Transaksjonshistorikk
Klikk på lenkeikonet for å se hele transaksjonshistorikken. Transaksjoner rapportert som en del av en automatisk handelsplan 10b5-1 vil ha en X i kolonnen merket 10b-5.
| Fil dato |
Handels dato |
Skjema | Innsider | Ticker | Verdipapirnavn | Kode | Direkte | Utøvelses pris |
Enhets pris |
Enheter endret |
Verdi endret (1K) |
Gjenværende Opsjoner |
Gjenværende Aksjer |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023-09-08 | 2023-09-08 | 4 | Prime Movers Lab Fund I LP Held by Prime Movers Growth Fund 1 LP | VAXX | Class A common stock | I | 1,6700 | −10 349 | −17 | 3 594 122 | ||||
| 2023-09-08 | 2023-09-08 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A common stock | I | 1,6700 | −4 217 | −7 | 1 464 578 | ||||
| 2023-09-08 | 2023-09-08 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 1,6700 | −2 395 | −4 | 831 658 | ||||
| 2023-09-08 | 2023-09-08 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A common stock | D | 1,6700 | −25 089 | −42 | 8 713 663 | ||||
| 2023-09-08 | 2023-09-08 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A common stock | I | 1,6700 | −5 911 | −10 | 2 053 079 | ||||
| 2023-09-08 | 2023-09-07 | 4 | Prime Movers Lab Fund I LP Held by Prime Movers Growth Fund 1 LP | VAXX | Class A common stock | I | 1,7872 | −8 378 | −15 | 3 604 471 | ||||
| 2023-09-08 | 2023-09-07 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A common stock | I | 1,7872 | −3 413 | −6 | 1 468 795 | ||||
| 2023-09-08 | 2023-09-07 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 1,7872 | −1 939 | −3 | 834 053 | ||||
| 2023-09-08 | 2023-09-07 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 1,7872 | −20 312 | −36 | 8 738 752 | ||||
| 2023-09-08 | 2023-09-07 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 1,7872 | −4 786 | −9 | 2 058 990 | ||||
| 2023-09-08 | 2023-09-06 | 4 | Prime Movers Lab Fund I LP Held by Prime Movers Growth Fund 1 LP | VAXX | Class A Common Stock | I | 1,8823 | −2 189 | −4 | 3 612 849 | ||||
| 2023-09-08 | 2023-09-06 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A Common Stock | I | 1,8823 | −892 | −2 | 1 472 208 | ||||
| 2023-09-08 | 2023-09-06 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 1,8823 | −507 | −1 | 835 992 | ||||
| 2023-09-08 | 2023-09-06 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 1,8823 | −5 308 | −10 | 8 759 064 | ||||
| 2023-09-08 | 2023-09-06 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 1,8823 | −1 251 | −2 | 2 063 776 | ||||
| 2023-05-02 | 2023-04-26 | 4 | Diamandis Peter | VAXX | Class A common stock | D | 1,2100 | 46 500 | 56 | 906 141 | ||||
| 2023-05-02 | 2023-04-26 | 4 | Diamandis Peter | VAXX | Class A common stock | D | 0,5700 | 429 037 | 245 | 859 641 | ||||
| 2023-04-28 | 3/A | Smith James Alan By IO Fund, LLC | VAXX | Class A common stock | I | 54 202 | ||||||||
| 2023-04-28 | 3/A | Smith James Alan | VAXX | Class A common stock | D | 8 058 | ||||||||
| 2023-02-10 | 3 | Smith James Alan | VAXX | Class A common stock | D | 8 058 | ||||||||
| 2023-02-10 | 3 | Smith James Alan By IO Fund, LLC | VAXX | Class A common stock | I | 12 268 | ||||||||
| 2023-02-10 | 3 | Ogilvie Landon E By child | VAXX | Class A common stock | I | 32 850 | ||||||||
| 2023-01-25 | 2023-01-23 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A common stock | D | 3,3514 | −405 217 | −1 358 | 8 764 372 | ||||
| 2023-01-25 | 2023-01-23 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A common stock | I | 3,3514 | −95 475 | −320 | 2 065 027 | ||||
| 2022-12-05 | 2022-12-02 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,5682 | −11 121 | −29 | 9 169 589 | ||||
| 2022-12-05 | 2022-12-02 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,5682 | −2 620 | −7 | 2 160 502 | ||||
| 2022-12-05 | 2022-12-01 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,9717 | −270 964 | −805 | 9 180 710 | ||||
| 2022-12-05 | 2022-12-01 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,9717 | −63 843 | −190 | 2 163 122 | ||||
| 2022-09-08 | 2022-09-06 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,4029 | −25 243 | −61 | 9 451 674 | ||||
| 2022-09-08 | 2022-09-06 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A Common Stock | I | 2,4029 | −3 934 | −9 | 1 473 100 | ||||
| 2022-09-08 | 2022-09-06 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 2,4029 | −2 234 | −5 | 836 499 | ||||
| 2022-09-08 | 2022-09-06 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,4029 | −5 947 | −14 | 2 226 965 | ||||
| 2022-08-29 | 2022-08-22 | 4 | Guirakhoo Farshad | VAXX | Class A common stock | D | 0,5700 | 2 640 | 2 | 68 645 | ||||
| 2022-08-29 | 2022-08-15 | 4 | Guirakhoo Farshad | VAXX | Class A common stock | D | 0,5700 | 26 005 | 15 | 66 005 | ||||
| 2022-08-29 | 2022-07-29 | 4 | Guirakhoo Farshad | VAXX | Class A common stock | D | 0,5700 | 20 000 | 11 | 40 000 | ||||
| 2022-08-29 | 2022-01-13 | 4 | Guirakhoo Farshad | VAXX | Class A common stock | D | 0,5700 | 10 000 | 6 | 10 000 | ||||
| 2022-08-25 | 2022-08-25 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A common stock | D | 2,3310 | −22 757 | −53 | 9 476 917 | ||||
| 2022-08-25 | 2022-08-25 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A common stock | I | 2,3310 | −3 547 | −8 | 1 477 034 | ||||
| 2022-08-25 | 2022-08-25 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A common stock | I | 2,3310 | −2 014 | −5 | 838 733 | ||||
| 2022-08-25 | 2022-08-25 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A common stock | I | 2,3310 | −5 362 | −12 | 2 232 912 | ||||
| 2022-08-25 | 2022-08-24 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,3862 | −83 786 | −200 | 9 499 674 | ||||
| 2022-08-25 | 2022-08-24 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A Common Stock | I | 2,3862 | −13 058 | −31 | 1 480 581 | ||||
| 2022-08-25 | 2022-08-24 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 2,3862 | −7 415 | −18 | 840 747 | ||||
| 2022-08-25 | 2022-08-24 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,3862 | −19 741 | −47 | 2 238 274 | ||||
| 2022-08-25 | 2022-08-23 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,4466 | −33 785 | −83 | 9 583 460 | ||||
| 2022-08-25 | 2022-08-23 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A Common Stock | I | 2,4466 | −5 265 | −13 | 1 493 639 | ||||
| 2022-08-25 | 2022-08-23 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 2,4466 | −2 990 | −7 | 848 162 | ||||
| 2022-08-25 | 2022-08-23 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,4466 | −7 960 | −19 | 2 258 015 | ||||
| 2022-06-23 | 2021-11-18 | 4/A | Diamandis Peter | VAXX | Class A common stock | D | 13,0000 | −248 | −3 | 90 499 | ||||
| 2022-06-23 | 2021-11-15 | 4/A | Diamandis Peter | VAXX | Class A common stock | D | 13 824 | 13 824 | ||||||
| 2022-06-23 | 2021-11-15 | 4/A | Diamandis Peter Held by spouse | VAXX | Class A common stock | I | 13 824 | 13 824 | ||||||
| 2022-06-23 | 2022-01-24 | 4/A | Diamandis Peter | VAXX | Class A common stock | D | 8,6000 | −312 659 | −2 689 | 430 604 | ||||
| 2022-06-21 | 2022-06-16 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 1,9929 | 100 000 | 199 | 51 737 344 | ||||
| 2022-06-21 | 2022-06-16 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 1,9929 | 100 000 | 199 | 51 737 344 | ||||
| 2022-06-21 | 2022-06-16 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 1,9929 | 100 000 | 199 | 51 737 344 | ||||
| 2022-06-14 | 2022-06-13 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,4259 | −92 569 | −225 | 9 617 245 | ||||
| 2022-06-14 | 2022-06-13 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A Common Stock | I | 2,4259 | −14 427 | −35 | 1 498 904 | ||||
| 2022-06-14 | 2022-06-13 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 2,4259 | −8 193 | −20 | 851 152 | ||||
| 2022-06-14 | 2022-06-13 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,4259 | −21 811 | −53 | 2 265 975 | ||||
| 2022-06-14 | 2022-06-10 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A Common Stock | D | 2,7981 | −28 378 | −79 | 9 709 814 | ||||
| 2022-06-14 | 2022-06-10 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A Common Stock | I | 2,7981 | −4 423 | −12 | 1 513 331 | ||||
| 2022-06-14 | 2022-06-10 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A Common Stock | I | 2,7981 | −2 512 | −7 | 859 345 | ||||
| 2022-06-14 | 2022-06-10 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A Common Stock | I | 2,7981 | −6 687 | −19 | 2 287 786 | ||||
| 2022-06-10 | 2022-06-09 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 2,7193 | 10 978 | 30 | 51 637 344 | ||||
| 2022-06-10 | 2022-06-08 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 2,9534 | 10 000 | 30 | 51 626 366 | ||||
| 2022-06-10 | 2022-06-09 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 2,7193 | 10 978 | 30 | 51 637 344 | ||||
| 2022-06-10 | 2022-06-08 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 2,9534 | 10 000 | 30 | 51 626 366 | ||||
| 2022-06-10 | 2022-06-09 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 2,7193 | 10 978 | 30 | 51 637 344 | ||||
| 2022-06-10 | 2022-06-08 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 2,9534 | 10 000 | 30 | 51 626 366 | ||||
| 2022-05-05 | 2022-05-03 | 4 | Guirakhoo Farshad | VAXX | Stock Option (right to buy) | D | 0,57 | −10 000 | 116 730 | |||||
| 2022-05-05 | 2022-05-03 | 4 | Guirakhoo Farshad | VAXX | Class A common stock | D | 0,5700 | 10 000 | 6 | 10 000 | ||||
| 2022-04-28 | 2022-04-27 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 3,5826 | 4 807 | 17 | 51 616 366 | ||||
| 2022-04-28 | 2022-04-26 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 3,4503 | 18 105 | 62 | 51 611 559 | ||||
| 2022-04-28 | 2022-04-27 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 3,5826 | 4 807 | 17 | 51 616 366 | ||||
| 2022-04-28 | 2022-04-26 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 3,4503 | 18 105 | 62 | 51 611 559 | ||||
| 2022-04-28 | 2022-04-27 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 3,5826 | 4 807 | 17 | 51 616 366 | ||||
| 2022-04-28 | 2022-04-26 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 3,4503 | 18 105 | 62 | 51 611 559 | ||||
| 2022-04-27 | 2022-04-25 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 3,3681 | 8 038 | 27 | 51 593 454 | ||||
| 2022-04-27 | 2022-04-25 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 3,3681 | 8 038 | 27 | 51 593 454 | ||||
| 2022-04-27 | 2022-04-25 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 3,3681 | 8 038 | 27 | 5 193 454 | ||||
| 2022-04-04 | 2022-03-31 | 4 | Powchik Peter | VAXX | Stock Option (right to buy) | D | 4,30 | 94 186 | 94 186 | |||||
| 2022-04-04 | 3 | Powchik Peter | VAXX | Class A common stock | D | 225 858 | ||||||||
| 2022-03-15 | 2022-03-15 | 4 | Palm Ulo | VAXX | Restricted Stock Units | D | 100 000 | 100 000 | ||||||
| 2022-01-26 | 2022-01-24 | 4 | Diamandis Peter | VAXX | Stock Option (right to buy) | D | 4,12 | −652 764 | 163 191 | |||||
| 2022-01-26 | 2022-01-24 | 4 | Diamandis Peter | VAXX | Class A common stock | D | 4,1192 | 652 764 | 2 689 | 729 687 | ||||
| 2022-01-11 | 2022-01-03 | 4 | Pesile Jason | VAXX | Stock Option (right to buy) | D | 5,96 | 51 225 | 51 225 | |||||
| 2022-01-06 | 2021-12-31 | 4 | Chui James | VAXX | Class A common stock | D | 5,4800 | 6 000 | 33 | 14 000 | ||||
| 2022-01-05 | 2022-01-03 | 4 | HORNIG GEORGE R | VAXX | Stock Option (right to buy) | D | 5,96 | 67 953 | 67 953 | |||||
| 2021-12-14 | 2021-12-10 | 4 | Chui James | VAXX | Class A common stock | D | 7,8900 | 8 000 | 63 | 8 000 | ||||
| 2021-11-18 | 2021-11-16 | 4 | BLATT GREGORY R | VAXX | Class A common stock | D | 76 923 | 76 923 | ||||||
| 2021-11-18 | 2021-11-16 | 4 | BLATT GREGORY R Held by Bald Eagle IV LLC | VAXX | Class A common stock | I | −76 923 | 0 | ||||||
| 2021-11-18 | 2021-11-18 | 4 | Diamandis Peter | VAXX | Class A common stock | D | 76 923 | 76 923 | ||||||
| 2021-11-18 | 2021-11-18 | 4 | Diamandis Peter Held by Bald Eagle IV LLC | VAXX | Class A common stock | I | −76 923 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Diamandis Peter Held by spouse | VAXX | Series A preferred stock | I | −21 511 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Diamandis Peter Held by Bald Eagle IV LLC | VAXX | Class A common stock | I | 76 923 | 76 923 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Diamandis Peter Held by spouse | VAXX | Class A common stock | I | 271 655 | 271 655 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by The Gregory R. Blatt 2020 Annuity Trust III | VAXX | Series B preferred stock | I | −250 000 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by The Gregory R. Blatt 2020 Annuity Trust IX | VAXX | Series A preferred stock | I | −83 329 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by Blatt Family Investments LLC | VAXX | Series A preferred stock | I | −968 636 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by Bald Eagle IV LLC | VAXX | Class A common stock | I | 76 923 | 76 923 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by The Gregory R. Blatt 2020 Annuity Trust III | VAXX | Class A common stock | I | 160 668 | 160 668 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by The Gregory R. Blatt 2020 Annuity Trust IX | VAXX | Class A common stock | I | 53 553 | 53 553 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | BLATT GREGORY R Held by Blatt Family Investments LLC | VAXX | Class A common stock | I | 622 516 | 622 516 | ||||||
| 2021-11-15 | 2021-11-11 | 4 | Guirakhoo Farshad | VAXX | Stock option (right to buy) | D | 13,00 | 41 958 | 41 958 | |||||
| 2021-11-15 | 2021-11-11 | 4 | Paula Molina Rene | VAXX | Stock option (right to buy) | D | 13,00 | 96 153 | 96 153 | |||||
| 2021-11-15 | 2021-11-15 | 4 | Reese Lou Held by United Biomedical Inc., Asia | VAXX | Series A preferred stock | I | −6 554 643 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Series A preferred stock | I | −384 410 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Reese Lou Held by Blackfoot Healthcare Ventures LLC | VAXX | Series A preferred stock | I | −422 696 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Reese Lou Held by United Biomedical Inc., Asia | VAXX | Class A common stock | I | 4 212 495 | 4 212 495 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Reese Lou Held by United Biomedical Inc. | VAXX | Class A common stock | I | 247 050 | 51 585 416 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Reese Lou Held by Blackfoot Healthcare Ventures LLC | VAXX | Class A common stock | I | 271 655 | 271 655 | ||||||
| 2021-11-15 | 2021-11-12 | 4 | Reese Lou | VAXX | Class A common stock | D | 13,8240 | 17 500 | 242 | 17 500 | ||||
| 2021-11-15 | 2021-11-15 | 4 | Palm Ulo Held by spouse | VAXX | Class A common stock | I | 13,0000 | 450 | 6 | 450 | ||||
| 2021-11-15 | 2021-11-11 | 4 | Palm Ulo | VAXX | Stock option (right to buy) | D | 13,00 | 233 100 | 233 100 | |||||
| 2021-11-15 | 2021-11-15 | 4 | Hu Mei Mei Held by United Biomedical Inc., Asia | VAXX | Series A preferred stock | I | −6 554 643 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Series A preferred stock | I | −384 410 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Hu Mei Mei Held by Blackfoot Healthcare Ventures LLC | VAXX | Series A preferred stock | I | −422 696 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Hu Mei Mei Held by United Biomedical Inc., Asia | VAXX | Class A common stock | I | 4 212 495 | 4 212 495 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Hu Mei Mei Held by United Biomedical Inc. | VAXX | Class A common stock | I | 247 050 | 51 585 416 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Hu Mei Mei Held by Blackfoot Healthcare Ventures LLC | VAXX | Class A common stock | I | 271 655 | 271 655 | ||||||
| 2021-11-15 | 2021-11-12 | 4 | Hu Mei Mei Held by spouse | VAXX | Class A common stock | I | 13,8240 | 17 500 | 242 | 17 500 | ||||
| 2021-11-15 | 2021-11-15 | 4 | UNITED BIOMEDICAL INC Held by United Biomedical Inc., Asia | VAXX | Series A preferred stock | I | −6 554 643 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | UNITED BIOMEDICAL INC | VAXX | Series A preferred stock | D | −384 410 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | UNITED BIOMEDICAL INC Held by United Biomedical Inc., Asia | VAXX | Class A common stock | I | 4 212 495 | 4 212 495 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 247 050 | 51 585 416 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP | VAXX | Series A preferred stock | D | −15 152 627 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by Prime Movers Growth Fund 1 LP | VAXX | Series B preferred stock | I | −5 625 000 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Series A preferred stock | I | −2 361 626 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Series A preferred stock | I | −1 341 050 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Series A preferred stock | I | −3 570 201 | 0 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP | VAXX | Class A common stock | D | 9 738 192 | 9 738 192 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by Prime Movers Growth Fund 1 LP | VAXX | Class A common stock | I | 3 615 038 | 3 615 038 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 3 LP | VAXX | Class A common stock | I | 1 517 754 | 1 517 754 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 2 LP | VAXX | Class A common stock | I | 861 857 | 861 857 | ||||||
| 2021-11-15 | 2021-11-15 | 4 | Prime Movers Lab Fund I LP Held by COVAXX PML SPV 1 LP | VAXX | Class A common stock | I | 2 294 473 | 2 294 473 | ||||||
| 2021-11-10 | 3 | UNITED BIOMEDICAL INC | VAXX | Class A common stock | D | 51 338 366 | ||||||||
| 2021-11-10 | 3 | Doran Martin | VAXX | Class A common stock | D | 22 688 | ||||||||
| 2021-11-10 | 3 | Hu Mei Mei Held by United Biomedical Inc. See Note | VAXX | Class A common stock | I | 51 338 366 | ||||||||
| 2021-11-10 | 3 | Hu Mei Mei Held by spouse. See Note | VAXX | Class B common stock | I | 3 955 512 | ||||||||
| 2021-11-10 | 3 | Hu Mei Mei | VAXX | Class B common stock | D | 5 518 961 | ||||||||
| 2021-11-10 | 3 | Diamandis Peter | VAXX | Class B common stock | D | 1 099 915 | ||||||||
| 2021-11-10 | 3 | Reese Lou Held by spouse. See Note | VAXX | Class B common stock | I | 5 518 961 | ||||||||
| 2021-11-10 | 3 | Reese Lou | VAXX | Class B common stock | D | 3 955 511 | ||||||||
| 2021-11-10 | 3 | Reese Lou Held by United Biomedical Inc. See Note | VAXX | Class A common stock | I | 51 338 366 |
P
Åpent marked eller private kjøp av ikke-derivat eller derivat sikkerhet.
S
Åpent marked eller private kjøp av ikke-derivat eller derivat sikkerhet.
A
Bevilgning, tildeling eller andre oppkjøp av verdipapirer fra selskapet (slik som en opsjon)
C
Konvertering av derivat
D
Salg eller overføring av verdipapirer tilbake til selskapet
F
Betaling av utøvelseskurs eller skatteplikt ved å bruke deler av verdipapirer mottat fra selskapet
G
Gave av verdipapirer fra eller til insidere
K
Aksjebytting og lignende sikringsavtaler
M
Øvelse eller konvertering av derivatverdipapir mottatt fra selskapet (for eksempel en opsjon)
V
En transaksjon frivilig rapportert på Skjema 4
J
Annet (med en fotnote som beskriver transaksjonen)
